SECOND EXTENSION - GRANTED
granted
on 20 Sep 2024
Last Applicant/ Owned by
2450 Perimeter Park Dr.
Morrisville
NC
27560
Serial Number
97704083 filed on 05th Dec 2022
Registration Number
N/A
Correspondent Address
Philip J. Cardinale
Philip J. Cardinale SMITH ANDERSON BLOUNT DORSETT MITCHELL & JERNIGAN
RALEIGH, NC 27602
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
OUTLAST
Reagents for research purposes, drug discovery and development; Reagents for clinical cancer treatment research; biotechnology platform for developing and engineering therapeutic cells for drug research and development, consisting of therapeutic proteins and therapeutic antibodies for the treatment of cancer; biotechnology platform for developing and engineering therapeutic cells, consisting of CA Read More
Classification Information
Class [005]
Pharmaceutical Products
Biological preparations, namely, preparations for use in the treatment of cancer; biologic preparations for medical and therapeutic purposes for immunotherapy; biological preparations for immunotherapy, namely, T-Cell therapy; cells for medical or clinical use; pharmaceutical preparations and therapeutic agents for the treatment of cancer; medical diagnostic reagents for the treatment of cancer; therapeutic preparations in the nature of an engineered cell therapy platform consisting of CAR-T cells for the treatment of cancer; biotechnology platform for the treatment of cancer through developing and engineering therapeutic cells, consisting of CAR-T cells, therapeutic medical antibodies, therapeutic agents and cellular function activating agents; clinical medical reagents for the treatment of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Reagents for research purposes, drug discovery and development; Reagents for clinical cancer treatment research; biotechnology platform for developing and engineering therapeutic cells for drug research and development, consisting of therapeutic proteins and therapeutic antibodies for the treatment of cancer; biotechnology platform for developing and engineering therapeutic cells, consisting of CAR-T cells, therapeutic medical antibodies, therapeutic agents and cellular function activating agents for the treatment of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97704083
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 16789.8
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 20th Sep 2024 | SOU EXTENSION 2 GRANTED |
| 20th Sep 2024 | SOU EXTENSION 2 FILED |
| 20th Sep 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 20th Sep 2024 | SOU TEAS EXTENSION RECEIVED |
| 23rd Apr 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 22nd Apr 2024 | SOU EXTENSION 1 GRANTED |
| 22nd Apr 2024 | SOU EXTENSION 1 FILED |
| 22nd Apr 2024 | SOU TEAS EXTENSION RECEIVED |
| 31st Oct 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 05th Sep 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |